Frick R W
State University of New York at Stony Brook, NY, USA.
Angiology. 2000 Mar;51(3):197-205. doi: 10.1177/000331970005100303.
Escin, hydroxyethylrutoside (HR), and Daflon have been shown to be safe and effective for the treatment of chronic venous insufficiency (CVI). They seem to work differently than compression therapy, suggesting that they would usefully augment this therapy. All three phlebotonics attenuate the drop in adenosine triphosphate in venous endothelial cells during hypoxia. This attenuates (1) the inflammation response, (2) the attraction of neutrophils, (3) damage to the veins, and (4) the release of growth factors. These factors otherwise would perpetuate venous insufficiency and contribute to varicose veins. Additional independent effects that would be useful for the treatment of CVI are that they reduce permeability and fragility; HR, Daflon, and perhaps escin increase venous tone; escin inhibits hyaluronidase; Daflon and probably HR are attracted to the veins. With regard to similarity, no differences in effect have been established among these phlebotonics.
七叶皂苷、羟乙基芦丁（HR）和达氟龙已被证明对治疗慢性静脉功能不全（CVI）安全有效。它们的作用机制似乎与压迫疗法不同，这表明它们可有效增强这种疗法。所有这三种静脉活性药物都能减轻缺氧期间静脉内皮细胞中三磷酸腺苷的下降。这会减轻（1）炎症反应，（2）中性粒细胞的吸引，（3）静脉损伤，以及（4）生长因子的释放。否则，这些因素会使静脉功能不全持续存在并导致静脉曲张。对治疗CVI有用的其他独立作用包括它们降低通透性和脆性；HR、达氟龙以及可能还有七叶皂苷可增加静脉张力；七叶皂苷抑制透明质酸酶；达氟龙以及可能还有HR会被静脉吸引。关于相似性，尚未确定这些静脉活性药物在效果上有差异。
